Prostate Cancer Screening Advances: New Data and Consensus Recommendations
Nearly 300 abstracts on prostate cancer research from around the world were presented at the European Association of Urology Congress (EAU26), held in London from March 13–16, 2026. These presentations highlighted significant progress in prostate cancer screening, focusing on improving accuracy, reducing overdiagnosis, and minimizing unnecessary harms.
Long-Term Screening Benefits Confirmed
Data from the Gothenburg 1 study, a 30-year trial led by Jonas Hugosson, confirms that prostate cancer screening reduces mortality. The study, which began in 1994 with 20,000 men aged 50–64, showed that screening averted one death for every 311 men invited to screening after 15 years, and one death for every 161 men after 30 years. Screening averted one death for every 13 men diagnosed after 15 years and every 6 men diagnosed after 30 years.
Despite the benefits, the study also noted a higher incidence of prostate cancer in the screening group. However, researchers acknowledge that advancements in diagnostic pathways, particularly the leverage of MRI and risk stratification, are helping to reduce the detection of insignificant cancers. European Association of Urology
MRI and Risk Stratification: Refining Screening Approaches
A key focus of current research is optimizing the use of MRI in prostate cancer screening. International consensus recommendations, developed by 21 experts from Europe and North America, aim to standardize MRI usage to detect significant cancers while reducing overdiagnosis and unnecessary biopsies. These recommendations, known as PRISM, detail when and how to best use MRI, how to interpret the results, and when to trigger a biopsy or further screening. EurekAlert!
Reducing Unnecessary Referrals
Preliminary data from the PRAISE-U study indicates that incorporating risk stratification, using tools like PSA-density or the Rotterdam Prostate Cancer Risk calculator (RPCRC), can reduce MRI referrals by 40–60% when used in addition to PSA testing. Centers using the RPCRC with transrectal ultrasound saw the greatest reduction in unnecessary MRIs.
Stockholm3 Biomarker Test Improves Accuracy
A trial in Sweden demonstrated that the Stockholm3 blood test, which combines protein and genetic biomarkers with clinical information, can significantly reduce the need for MRI referrals, and biopsies. The test, used before MRI in men with a PSA of 2 ng/ml or higher, led to a 67% reduction in MRI scans.
Psychological Impact of Screening Remains Low
Research presented at EAU26 suggests that while around a quarter of men feel worried during prostate cancer screening, severe anxiety is rare. A study of 692 men with elevated PSA levels found that only 3.8–4.8% reported moderate to severe anxiety after referral for MRI and biopsy. The greatest distress was reported just before the biopsy, with 26% of men feeling worried, but only 4.2% reporting it affected their daily life.
Expert Perspective
Tobias Nordström, a clinical urologist and Associate Professor at the Karolinska Institute in Sweden, and a member of the EAU Scientific Congress Office, emphasized the importance of balancing the benefits of screening with minimizing harm. “The field of prostate cancer screening is advancing all the time,” he said. “We know that screening can save lives…research has focused on reducing overdiagnosis and unnecessary harms while maintaining the benefits in saving lives.” Karolinska Institutet, EurekAlert!